Jamie Christensen - Sep 7, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
EVP, Chief Scientific Officer
Signature
/s/ Reena Desai, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Sep 7, 2022
Transactions value $
$0
Form type
4
Date filed
9/9/2022, 05:35 PM
Previous filing
Jun 14, 2022
Next filing
Dec 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +19.1K +22.03% $0.00 106K Sep 7, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares from a Performance Share Unit Award where the performance requirements were deemed as achieved by the Board of Director on 09/07/22. Shares will vest 25% annually on the anniversary of the goal achievement date until fully vested
F2 Includes 136 shares acquired under the ESPP Purchase on 5/31/22